Lisa Rodríguez

MedicineEconomics, Econometrics and Finance

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors”.

FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0327

N/A

0DataRank · unranked

580 citations

Lola A. Fashoyin‐Aje, Martha Donoghue, Mengdie Yuan, Lisa Rodríguez, Pamela Gallagher +7 more

FDA Approval Summary: Nivolumab with Ipilimumab and Chemotherapy for Metastatic Non–small Cell Lung Cancer, A Collaborative Project Orbis Review

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4338

N/A

0DataRank · unranked

57 citations

Flora Mulkey, Adnan A. Jaigirdar, Lisa Rodríguez, Yibo Wang, Yuan Xu +14 more